Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.31	$0.34	$0.27 ▼ $1.23	$63.38M	1.03	116,627 shs	55,205 shs
IMMP Prima BioMed	$1.64 +0.6%	$1.80	$1.32 ▼ $2.72	$239.51M	1.76	193,592 shs	56,504 shs
NGNE Neurogene	$16.16 -2.5%	$17.33	$6.88 ▼ $74.49	$230.44M	1.57	245,348 shs	436,968 shs
PVLA Palvella Therapeutics	$22.08 +7.1%	$23.54	$6.20 ▼ $29.27	$244.21M	-0.1	136,637 shs	1.14 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	0.00%	+6.90%	-3.16%	-11.43%	-65.93%
IMMP Prima BioMed	0.00%	+2.50%	-14.14%	-6.82%	-18.41%
NGNE Neurogene	0.00%	-9.01%	-6.10%	+38.00%	-55.59%
PVLA Palvella Therapeutics	0.00%	+0.14%	-9.14%	-21.11%	+2,207,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	1.3364 of 5 stars	0.0	3.0	2.5	1.7	1.3
IMMP Prima BioMed	1.4241 of 5 stars	3.5	1.0	2.7	0.0	0.0
NGNE Neurogene	3.7799 of 5 stars	4.4	3.0	2.7	1.7	1.3
PVLA Palvella Therapeutics	3.2702 of 5 stars	3.6	0.0	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	4.00	Strong Buy	N/A	N/A
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	185.68% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	109.63% Upside

Current Analyst Ratings Breakdown

Latest AAWH, NGNE, IMMP, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.12	$0.05 per share	6.64	$0.69 per share	0.45
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56
NGNE Neurogene	$930K	247.79	N/A	N/A	$20.89 per share	0.77
PVLA Palvella Therapeutics	$42.81M	5.70	N/A	N/A	$5.58 per share	3.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.40	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)

Latest AAWH, NGNE, IMMP, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
IMMP Prima BioMed	N/A	18.86	N/A
NGNE Neurogene	N/A	21.03	21.03
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.31%
IMMP Prima BioMed	2.32%
NGNE Neurogene	52.37%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.08%
IMMP Prima BioMed	3.07%
NGNE Neurogene	9.92%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.44 million	166.44 million	Not Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

AAWH, NGNE, IMMP, and PVLA Headlines

Recent News About These Companies

Strid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)

June 29 at 7:47 AM | marketbeat.com

PVLA - Palvella Therapeutics Inc Key Metrics - Morningstar

June 27 at 8:01 PM | morningstar.comM

PVLA - Palvella Therapeutics Inc Executives - Morningstar

June 26, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...

June 24, 2025 | manilatimes.netM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - Morningstar

June 24, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - Nasdaq

June 24, 2025 | nasdaq.com

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin

June 24, 2025 | msn.com

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026

June 23, 2025 | quiverquant.comQ

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

June 23, 2025 | globenewswire.com

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18, 2025 | globenewswire.com

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13, 2025 | msn.com

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

June 11, 2025 | marketbeat.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.comQ

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

June 9, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)

June 2, 2025 | marketbeat.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 30, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.comA

Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position

May 16, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAWH, NGNE, IMMP, and PVLA Company Descriptions

Ascend Wellness OTC:AAWH

$0.31 0.00 (0.00%)

As of 06/27/2025 03:58 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.62 -0.02 (-1.52%)

As of 04:05 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Neurogene NASDAQ:NGNE

$16.16 -0.41 (-2.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.16 0.00 (-0.03%)

As of 04:03 AM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Palvella Therapeutics NASDAQ:PVLA

$22.08 +1.46 (+7.08%)

As of 06/27/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time